The MDx Impact Grants aim to unlock the potential of PCR to democratise access to accurate diagnostic tests that improve patient outcomes.
We invite research groups to work with us and our partner Seegene to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants of up to 600,000 USD to perform clinical studies.
Each research group is permitted to submit only one application focused on the designated project. We welcome applications from eligible research groups from around the world.
2025 Scope: Urinary Tract Infection (UTI) Drug Resistance (DR)
This year, the MDx Impact Grants focus on Urinary Tract Infection (UTI) Drug Resistance (DR) genes that correspond to clinically important antibiotic resistance genes, such as, CTX-M, KPC, NDM and vanA. Your proposal must include a minimum of nine (9) and up to a maximum of eighteen (18) target genes excluding internal controls.
Open date -2 September 2025
Close date- (23:59 GMT) 20 November 2025
November 2025 to August 2026
Successful applicants notified -Mid-August 2026